Champions Oncology, Inc. (CSBR) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals mixed signals: stable revenue with signs of recovery but increased costs leading to a loss. The data business shows potential growth, but management's vague responses in the Q&A about future opportunities and revenue guidance create uncertainty. Operational inefficiencies and increased expenses further complicate the outlook. Despite optimism in some areas, the lack of clear guidance and current financial strain suggest a neutral stock movement in the short term.
Key Financial Performance
Revenue $14 million in Q1 fiscal 2026, flat year-over-year but a rebound from $12.4 million in Q4 fiscal 2025. The rebound was attributed to growth in the TOS business and contributions from the emerging data platform.
Research Services Revenue $13.7 million in Q1 fiscal 2026, contributing the majority of the total revenue.
Data Business Revenue Balance of the $14 million total revenue in Q1 fiscal 2026, showing growth as it generated sales for three consecutive quarters.
Loss from Operations (GAAP) $0.5 million in Q1 fiscal 2026 compared to income from operations of $1.3 million in Q1 fiscal 2025. The loss included $600,000 in noncash expenses such as stock-based compensation and depreciation.
Adjusted EBITDA $60,000 in Q1 fiscal 2026, down from $2 million in Q1 fiscal 2025. The decline was due to increased costs and investments in R&D and sales and marketing.
Gross Margin 43% in Q1 fiscal 2026, down from 50% in Q1 fiscal 2025. The decline was primarily due to increased outsourced lab service costs for radio labeling work, which is expected to improve as the work is brought in-house.
Operating Expenses $6 million in Q1 fiscal 2026, up $1 million year-over-year. The increase was driven by $0.6 million in R&D, $0.2 million in sales and marketing, and $0.2 million in G&A expenses.
Cash Position $10.3 million at the end of Q1 fiscal 2026, up $0.5 million from year-end. The company remains debt-free and had positive operating cash flow of $0.6 million.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Radiopharmaceutical services platform: Expanded radioactive materials license, new radiochemistry infrastructure, and over 30 screened PDX models enable fully integrated workflows from biodistribution to efficacy testing on clinically relevant tumor models.
Data platform: Generated data sales for 3 consecutive quarters, leveraging a uniquely characterized PDX bank to create a comprehensive and clinically relevant tumor data set.
Corellia drug discovery subsidiary: Continues to advance with compelling data from platform and in vivo experiments, despite funding headwinds in biotech.
TOS business: Growth led by TOS business with contributions from the emerging data platform, supported by improving trends in biotech funding and R&D budgets.
Large pharma relationships: Growing relationships with large pharma creating opportunities for larger, more durable bookings.
Revenue: Achieved $14 million in Q1 revenue, rebounding from $12.4 million in Q4.
Gross margin: Declined to 43% from 50% in Q1 last year due to increased outsourced lab service costs for radio labeling work, with expectations of margin expansion as work is brought in-house.
Operating expenses: Increased by $1 million year-over-year, driven by R&D, sales and marketing, and IT costs.
Cash position: Ended Q1 with $10.3 million in cash, up $0.5 million from year-end, and remained debt-free.
Radiopharma and data initiatives: Advanced strategic initiatives in radiopharma and data, reinforcing the foundation for long-term success.
Cost management: Focused on disciplined cost management and streamlining system inefficiencies to support growth.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Biotech Funding and R&D Budget Pressures: The macro environment remains challenging with biotech funding and R&D budgets still under pressure, which could impact customer spending and growth opportunities.
Customer Cancellations and Revenue Conversion: Although improving, customer cancellations and bookings to revenue conversion remain areas of concern, potentially affecting revenue stability.
Gross Margin Decline: Gross margin declined from 50% to 43% year-over-year, primarily due to increased outsourced lab service costs for radio labeling work. This could impact profitability until the work is brought in-house.
Operating Loss: The company recorded a GAAP operating loss of $0.5 million compared to income from operations of $1.3 million in the same quarter last year, indicating financial pressure.
Increased Operating Expenses: Operating expenses rose by $1 million year-over-year, driven by higher R&D, sales and marketing, and G&A costs. While some increases are strategic, they could strain financials if not managed effectively.
System Inefficiencies: Temporary increases in G&A costs are attributed to system inefficiencies, which could hinder operational efficiency and increase costs if not resolved.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: The company expects sequential revenue growth in the upcoming quarters of fiscal 2026, building on the $14 million reported in Q1.
Profitability: Champions Oncology anticipates continued profitability on an adjusted EBITDA basis in the near term.
Margin Expansion: Gross margins are expected to expand as radio labeling work is brought in-house, reducing outsourced lab service costs.
Cash Flow: The company projects to remain roughly cash neutral in Q2 and expects cash growth in the second half of fiscal 2026 as revenues increase and margins expand.
Data Business Growth: Investments in the data business are expected to support growth in the coming quarters, leveraging the company's uniquely characterized PDX bank and the increasing role of AI and machine learning in drug discovery.
Radiopharmaceutical Services: The company is expanding its radiopharmaceutical services platform, which is expected to reduce costs, improve gross margins, and offer fully integrated workflows in a fast-growing field.
Corellia Drug Discovery: Corellia, the company's drug discovery subsidiary, is expected to translate its compelling data and in vivo experiments into meaningful investment opportunities despite funding headwinds in biotech.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Is there any changes in the strategy on either the business model or go-to-market with the data licensing business?
A:There are no changes in the strategy. The company has had some early wins and sees potential in the data licensing business. Customer engagement and excitement are evident, and the pipeline is building. However, it is still early, and updates will be provided in the coming quarters.
Q:How would you characterize the size of the opportunity of this business relative to the traditional business you have?
A:It is still early to predict the exact size and success of the opportunity. There is potential and interest, and the data is fueling AI and ML models for drug discovery and development. The extent of the opportunity will become clearer as deals are executed.
Q:What are some of the frameworks you are entertaining and structuring deals with Corellia?
A:Corellia is a wholly owned subsidiary, and the company is actively raising funds to support it. They are looking for external partners and funding to advance its work. The data from Corellia is compelling, and external investment is sought to drive progress.
Q:Can you provide some color on the broader investment landscape and what you're seeing from customers?
A:The environment remains tough, but there are signs of improvement. Budget constraints are easing, and the company is cautiously optimistic. They feel well-positioned with their proprietary tumor bank and internal process improvements to capitalize on opportunities as the market improves.
Q:Would you consider a stabilization period to be more in the first half of this year?
A:The CFO, David Miller, stated that this is potentially the low point for the fiscal year in terms of revenue. Revenue is expected to expand over the coming quarters, with gradual building in the services business. The timing of data deals will also impact revenue growth.
Q:Do you have any color on Q2 so far on revenue compared to last year?
A:The company has a good handle on revenue but is not providing specific guidance. Revenue is expected to increase on a quarterly basis, but exact numbers or percentages are not being disclosed at this time.
Q:Review of Unclear Management Responses
A:Management avoided providing specific guidance on Q2 revenue compared to last year, stating they are not ready to disclose exact numbers or percentages. Additionally, the CEO mentioned it is still early to predict the size and success of the data licensing business opportunity, and the CFO highlighted uncertainty regarding the timing of data deals impacting revenue growth.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CFO today
Champions chapter
Champions focus
Champions softness
Champions term
Corellia TOS
Customer cancellation
Directors Champions
Oncology value
SEC Champions
TOS contribution
TOS platform
ability value
afternoon CEO
biodistribution efficacy
biopharma environment
biotech work
booking progress
budget pressure
chapter talent
characterization resource
confidence line
contribution platform
conversion relationship
customer offering
deal sale
discovery subsidiary
discovery term
drug discovery
environment funding
experiment funding
field work
filing SEC
focus foundation
foundation industry
foundation term
funding RD
funding headwind
opportunity Corellia
platform momentum
CSBR Transcript
Champions Oncology, Inc. (CSBR) Q3 2026 Earnings Call Transcript
Unknown3-12
The earnings call presents mixed signals: a decline in year-over-year revenue and gross margins, and increased operating expenses, are concerning. However, positive adjusted EBITDA, growth in core study revenue, and strategic investments in data and radiopharmaceuticals offer optimism. The absence of Q&A questions limits further sentiment insight. Given these mixed factors, the stock price is likely to remain stable over the next two weeks.
Champions Oncology, Inc. (CSBR) Q2 2026 Earnings Call Transcript
Positive12-15
The earnings call highlights several positives: revenue growth, margin expansion, and a strong cash position. Gross margins improved significantly, and the company anticipates further expansion. Although operating expenses increased due to strategic investments, the funding environment is improving, and cancellations have returned to historic levels. The Q&A session revealed optimism about market recovery and strategic hires to boost the data business. Despite some uncertainties, the overall sentiment is positive, with expectations of continued growth and profitability, likely resulting in a stock price increase of 2% to 8%.
Champions Oncology, Inc. (CSBR) Q1 2026 Earnings Call Transcript
Unknown9-15
The earnings call reveals mixed signals: stable revenue with signs of recovery but increased costs leading to a loss. The data business shows potential growth, but management's vague responses in the Q&A about future opportunities and revenue guidance create uncertainty. Operational inefficiencies and increased expenses further complicate the outlook. Despite optimism in some areas, the lack of clear guidance and current financial strain suggest a neutral stock movement in the short term.
Champions Oncology (CSBR) Q4 2025 Earnings Call Transcript
Unknown7-25
The earnings call presents mixed signals. Financial performance shows positive trends with increased annual revenue and improved EBITDA, but quarterly metrics are weak, with declining Q4 revenue and margins. Product development shows promise in high-margin areas like radiopharmaceuticals, yet the Q&A reveals uncertainties in data licensing and partnerships. The company's cautious optimism about fiscal '26 and improved cash position are positives, but lack of specific guidance and rising expenses temper enthusiasm. Overall, the mixed financials and unclear growth prospects suggest a neutral short-term stock price reaction.
CSBR Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
